Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2904485 | 0.89 | POLB (0.46) | POLBOPRD1OPRK1GRM5GRM1 | |
| SCHEMBL3662831 | 0.89 | POLB (0.48) | POLBOPRD1OPRK1TACR1GPR119 | |
| SCHEMBL3792634 | 0.84 | TRPV1 (0.54) | POLBOPRD1OPRK1GRM5GRM1 | |
| SCHEMBL3787005 | 0.84 | POLB (0.50) | POLBOPRD1OPRK1GRM5GRM1 | |
| SCHEMBL3325436 | 0.83 | GPR119 (0.50) | POLBOPRD1OPRK1GRM5TACR1 | |
| SCHEMBL4055955 | 0.83 | POLB (0.47) | POLBOPRD1OPRK1TACR1GPR119 | |
| SCHEMBL3325729 | 0.82 | TACR1 (0.48) | OPRD1OPRK1TACR1GPR119KDM1A | |
| SCHEMBL25232430 | 0.81 | OPRD1 (0.50) | OPRD1OPRK1GRM5KDM1A | |
| SCHEMBL2950039 | 0.80 | POLB (0.47) | POLBOPRD1OPRK1GRM5GRM1 | |
| SCHEMBL31417126 | 0.79 | JAK2 (0.48) | OPRD1OPRK1TACR1GPR119NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831201-B1 | PIPERIDINE AND AZETIDINE DERIVATIVES AS GLYT1 INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-7655644-B2 | Piperidine and azetidine derivatives as GlyT1 inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090796-A1 | Piperidine And Azetidine Derivatives As Glyt1 Inhibitors | SLC6A7, SLC1A1, SLC1A2 | POLB 4337/4885OPRD1 250/4885OPRK1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.